<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00837564</url>
  </required_header>
  <id_info>
    <org_study_id>CBASP-1</org_study_id>
    <nct_id>NCT00837564</nct_id>
  </id_info>
  <brief_title>Cognitive Behavioural Analysis System of Psychotherapy (CBASp) Versus Escitalopram in Chronic Depression</brief_title>
  <official_title>Differential Responses to Cognitive Behavioural Analysis System of Psychotherapy (CBASP)Versus Escitalopram in Chronic Major Depression With and Without Early Trauma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Freiburg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital, Bonn</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Freiburg</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      60 patients with chronic major depressive disorder according to DSM-IV will be included into
      the study. Patients will be randomized to receive an open treatment either with CBASP, a
      psychotherapy for chronic depression, or pharmacological treatment with Escitalopram for 28
      weeks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The psychotherapeutic treatment with CBASP will be conducted in 2 weekly sessions for the
      first 4 weeks, one per week thereafter until week 9, followed by one session every 2 weeks
      for 20 more weeks. The starting dose for Escitalopram will be 10 mg/d for one week and will
      be increased to 20 mg/d after one week. The dosage can be reduced to 10 mg/d after day 7 to
      improve tolerance. Th MADRS-scale is the primary outcome measure; ratings will be performed
      by a blinded rater. If there is no improvement (reduction of less than 20% of the MADRS),
      patients will be crossed over in terms of adding the other treatment at week 8. Study
      patients will be asked to participate in fMRI, genetic and pharmacological substudies.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2009</start_date>
  <completion_date type="Anticipated">April 2011</completion_date>
  <primary_completion_date type="Anticipated">April 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Depressive symptomatology after 8 weeks after randomization as measured by the MADRS</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Depressive symptoms and remission 28 weeks after randomization; social, interpersonal and work function 28 weeks after randomization</measure>
    <time_frame>28 weeks after ranomization</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Chronic Depression</condition>
  <arm_group>
    <arm_group_label>CBASP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CBASP psychotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Escitalopram</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Escitalopram pharmacotherapy and clinical management</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>CBASP psychotherapy</intervention_name>
    <description>specific psychotherapy for chronic depression</description>
    <arm_group_label>CBASP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Escitalopram</intervention_name>
    <description>Escitalopram 10-20 mg once daily for the treatment of depression in combination with clinical management</description>
    <arm_group_label>Escitalopram</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronic MDD according to DSM-IV (modification: depressive symptomatology for at least
             one year), or recurrent MDE (third or greater episode with the immediately preceding
             episode being no more than 2.5 years before the onset of the present episode)

          -  Age 18-65

          -  Score of at least 18 on the Montgomery-Asberg-Rating Scale for Depression (MADRS)

        Exclusion Criteria:

          -  Acute risk for suicide

          -  History of psychotic symptoms, bipolar disorder or dementia

          -  Severe substance-related abuse or dependence disorder

          -  Schizotypal, antisocial or borderline personality disorder

          -  Serious medical condition

          -  Severe cognitive impairment

          -  Absence of a response to previous adequate trial of the study medication/CBASP

          -  Hypersensitivity to Escitalopram

          -  Treatment with a MAO-inhibitor within 1 week before the initiation of study treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claus Normann, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Freiburg, Dep. of Psychiatry</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dieter Schoepf, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Bonn, Clinic for Psychiatry and Psychotherapy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Bonn, Dept. of Psychiatry</name>
      <address>
        <city>Bonn</city>
        <zip>D-53105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dieter Schoepf, MD</last_name>
      <email>dieter.schoepf@ukb.uni-bonn.de</email>
    </contact>
    <investigator>
      <last_name>Dieter Schoepf, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Henrik Walter, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Freiburg, Dept. of Psychiatry and Psychotherapy</name>
      <address>
        <city>Freiburg</city>
        <zip>D-79104</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claus Normann, MD</last_name>
      <phone>+49-761-2706501</phone>
      <email>claus.normann@uniklinik-freiburg.de</email>
    </contact>
    <investigator>
      <last_name>Claus Normann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elisabeth Schramm, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 4, 2009</study_first_submitted>
  <study_first_submitted_qc>February 4, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 5, 2009</study_first_posted>
  <last_update_submitted>June 29, 2010</last_update_submitted>
  <last_update_submitted_qc>June 29, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 30, 2010</last_update_posted>
  <responsible_party>
    <name_title>Dr. Claus Normann</name_title>
    <organization>University of Freiburg, Dep. of Psychiatry, Germany</organization>
  </responsible_party>
  <keyword>chronic depression</keyword>
  <keyword>CBASP</keyword>
  <keyword>Escitalopram</keyword>
  <keyword>depression</keyword>
  <keyword>trauma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citalopram</mesh_term>
    <mesh_term>Dexetimide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

